Who are Spruce Biosciences, Inc.'s main suppliers?

Spruce Biosciences, Inc. (SPRB) key suppliers include: JEFFERIES-LLC, Eli Lilly and Company, Eli Lilly and Company, BioMarin Pharmaceutical Inc., BioMarin Pharmaceutical Inc. and 5 more. View the full supplier network at chainsifter.com/chain/SPRB.

Who are Spruce Biosciences, Inc.'s major customers?

Spruce Biosciences, Inc. (SPRB) key customers include: KAKEN-PHARMACEUTICAL-CO-LTD, BioMarin Pharmaceutical Inc., BioMarin Pharmaceutical Inc., Eli Lilly and Company, Eli Lilly and Company and 13 more. View the full customer network at chainsifter.com/chain/SPRB.

What sector is Spruce Biosciences, Inc. in?

Spruce Biosciences, Inc. (SPRB) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Spruce Biosciences, Inc. Suppliers, Customers & Supply Chain (SPRB)

10Suppliers

18Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Spruce Biosciences, Inc. (SPRB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

32Total relationships

6Distinct source URLs

11High confidence

0.769Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Spruce Biosciences, Inc. Suppliers

Ticker	Name	Confidence	Evidence
JEFFERIES-LLC	JEFFERIES-LLC	92%	Under the Sales Agreement, the Company may offer and sell, from time to time, through Jefferies as its sales agent and/or principal, shares (the “Shares”) of its common stock
LLY	Eli Lilly and Company	92%	Reciprocal relationship from LLY graph: Reciprocal relationship from SPRB graph: Pursuant to the terms of the Lilly License Agreement, Lilly granted us an exclusive, worldwide, royalty bearing, subli…
LLY	Eli Lilly and Company	92%	Pursuant to the terms of the Lilly License Agreement, Lilly granted us an exclusive, worldwide, royalty bearing, sublicensable license under certain technology, patent rights, know-how, and proprieta…
BMRN	BioMarin Pharmaceutical Inc.	90%	mmercial sale. In addition, we will also be entitled to receive a royalty for each unit of non-Company manufactured product sold equal to a range of double-digit percentages up to the mid-twenties ba…
BMRN	BioMarin Pharmaceutical Inc.	90%	Reciprocal relationship from BMRN graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from BMRN g…
HBM-ALPHA-THERAPEUTICS-INC	HBM-ALPHA-THERAPEUTICS-INC	90%	As consideration, the Company made a one-time upfront payment to HBM of $ 5.0 million in February 2025.
NBIX	Neurocrine Biosciences, Inc.	72%	Reciprocal relationship from NBIX graph: Reciprocal relationship from SPRB graph: her jurisdictions, all of which could seriously harm our business. 85 Table of Contents Item 1B. Unresolv ed Staff Co…
NBIX	Neurocrine Biosciences, Inc.	72%	her jurisdictions, all of which could seriously harm our business. 85 Table of Contents Item 1B. Unresolv ed Staff Comments. None. For example, cybersecurity risk is addressed as a component of the C…
TWST	Twist Bioscience Corporation	72%	Reciprocal relationship from TWST graph: Reciprocal relationship from SPRB graph: and time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the cri…
TWST	Twist Bioscience Corporation	72%	and time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions. Enfo…

Spruce Biosciences, Inc. Customers

Ticker	Name	Confidence	Evidence
KAKEN-PHARMACEUTICAL-CO-LTD	KAKEN-PHARMACEUTICAL-CO-LTD	92%	Under the terms of the Collaboration Agreement, the Company granted Kaken the exclusive right to develop, manufacture and commercialize tildacerfont for the treatment of congenital adrenal hyperplasi…
BMRN	BioMarin Pharmaceutical Inc.	72%	suance of the Avenue Warrant on March 9, 2026, the shares into which the Avenue Warrant will be issued became fixed and therefore the Company reassessed its accounting treatment under ASC 815-40-15-7…
BMRN	BioMarin Pharmaceutical Inc.	72%	Reciprocal relationship from BMRN graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from BMRN g…
LLY	Eli Lilly and Company	72%	. The following table summarizes the Company's financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): December 31, 2025 Total Level 1 Le…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from LLY graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from LLY grap…
MYGN	Myriad Genetics, Inc.	72%	governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide he…
MYGN	Myriad Genetics, Inc.	72%	Reciprocal relationship from MYGN graph: Reciprocal relationship from SPRB graph: governmental bodies to limit the scope of patent protection both inside and outside the United States for disease tre…
NBIX	Neurocrine Biosciences, Inc.	72%	Reciprocal relationship from NBIX graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from NBIX g…
NBIX	Neurocrine Biosciences, Inc.	72%	. The following table summarizes the Company's financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): December 31, 2025 Total Level 1 Le…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from SPRB graph: governmental bodies to limit the scope of patent protection both inside and outside the United States for disease tr…
SNYNF	Sanofi	72%	governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide he…
TWST	Twist Bioscience Corporation	72%	nadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of these events occurs or if we otherwise lose protection for our trade secr…
TWST	Twist Bioscience Corporation	72%	Reciprocal relationship from TWST graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from TWST graph: Reciprocal relationship from SPRB graph: nadvertently incorporated into the …
CELLECT-LLC	CELLECT-LLC	62%	governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide he…
HBM-ALPHA-THERAPEUTICS-INC	HBM-ALPHA-THERAPEUTICS-INC	62%	. The following table summarizes the Company's financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): December 31, 2025 Total Level 1 Le…
HMNC-HOLDING-GMBH	HMNC-HOLDING-GMBH	62%	. The following table summarizes the Company's financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): December 31, 2025 Total Level 1 Le…
LICENSE-AGREEMENTS-BIOMARIN-PHARMACEUTICAL-INC	LICENSE-AGREEMENTS-BIOMARIN-PHARMACEUTICAL-INC	62%	suance of the Avenue Warrant on March 9, 2026, the shares into which the Avenue Warrant will be issued became fixed and therefore the Company reassessed its accounting treatment under ASC 815-40-15-7…
NASDAQ-STOCK-MARKET-LLC	NASDAQ-STOCK-MARKET-LLC	62%	trial supplies, and other outside services; o other research and development—expenses associated with business operations, quality and regulatory compliance; and ▪ internal expenses, consisting of pe…

Spruce Biosciences, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
SPRB-DEBT-12710	Warrants outstanding: 57000	90%	xbrl warrant detail from xbrl 2025-12-31.
SPRB-DEBT-60637	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2026-01-07.
SPRB-DEBT	Debt stack $7.1M	90%	Market cache reports total debt of $7.1M.

Spruce Biosciences, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Spruce Biosciences, Inc..

Spruce Biosciences, Inc. Ownership

Holder	Name	Confidence	Evidence
SPRB-OWNER-IKARIAN-CAPITAL-LLC	Ikarian Capital, LLC	90%	13F overlay lists Ikarian Capital, LLC as top holder; 32 tracked holders.

Spruce Biosciences, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
EDSA	Edesa Biotech, Inc.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
AKTS	Aktis Oncology, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
FHTX	Foghorn Therapeutics Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
BNBX	BNB Plus Corp.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2

Spruce Biosciences, Inc. Supply Chain